Comparing 6-thioguanine and 6-mercaptopurine for treating childhood leukaemia
Author Information
Author(s): L. Lennard, H.A. Davies, J.S. Lilleyman
Primary Institution: University of Sheffield
Hypothesis
Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?
Conclusion
6-thioguanine is better tolerated and produces higher concentrations of cytotoxic metabolites than 6-mercaptopurine in children with certain genetic profiles.
Supporting Evidence
- 6-thioguanine produced significantly higher concentrations of intracellular cytotoxic metabolites than 6-mercaptopurine.
- Children with high TPMT activity had low concentrations of 6-TGN from 6-mercaptopurine.
- 6-thioguanine was well tolerated with minimal toxicity apart from myelosuppression.
Takeaway
This study looked at whether a different medicine, 6-thioguanine, works better than the usual one, 6-mercaptopurine, for kids with leukaemia. It found that 6-thioguanine might be a better choice for some kids.
Methodology
The study compared the pharmacokinetics of 6-thioguanine and 6-mercaptopurine in children with acute lymphoblastic leukaemia who were in remission.
Limitations
The study involved a small sample size and was conducted at a single center.
Participant Demographics
Seven children aged 6 to 13 years, including two girls and five boys, with a history of acute lymphoblastic leukaemia.
Statistical Information
P-Value
0.002
Confidence Interval
95% C.I. 743 to 1521
Statistical Significance
p=0.002
Want to read the original?
Access the complete publication on the publisher's website